Horizon Therapeutics: UPLIZNA Shows Durable Efficacy In African Americans With NMOSD

(RTTNews) - Horizon Therapeutics plc (HZNP) reported results of a retrospective analysis of the pivotal Phase 2/3 N-MOmentum trial, indicating UPLIZNA may provide durable efficacy and a favorable safety profile for African Americans with Neuromyelitis Optica Spectrum Disorder.

The N-MOmentum trial included a 28-week randomized controlled period, in which participants received UPLIZNA or placebo, followed by an optional open-label period during which all participants received UPLIZNA for at least two years. Among African American participants who received UPLIZNA during the randomized controlled period and/or optional open-label period, three of 19 had attacks 18, 29 and 104 days after their first UPLIZNA dose. In African American participants, UPLIZNA produced rapid and sustained B-cell depletion, consistent with other N-MOmentum trial participants, the company said.

UPLIZNA is the only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 antibody positive NMOSD.